JUN and neoplasm: The tumor-subtype and stage-dependent expression of JUN was highly significant when comparing healthy and primary (p = 2.8e-05), primary and metastatic CRPC (p = 2.6e-43) and primary and metastatic NEPC (p = 5.3e-04) (Supplementary Fig. 1g), suggesting JUN as a potential marker of progressive subtypes of PCa.